What does CRDF stand for?

Find the latest Cardiff Oncology, Inc. (CRDF) stock quote, history, news and other vital information to help you with your stock trading and investing.

Should you buy Cardiff Oncology Inc (CRDF) stock?

According to one analyst, the rating for CRDF stock is "Strong Buy" and the 12-month stock price forecast is $12.0. Cardiff Oncology Inc. CRDF, +0.62% shares surged 32% on favorable data from two cancer drug trials — metastatic pancreatic ductal adenocarcinoma and small cell lung cancer treatment.

Should you buy CRDF (CRDF) in 2022?

In 2022, CRDF's revenue was $386,000, an increase of 7.52% compared to the previous year's $359,000. Losses were -$38.73 million, 36.8% more than in 2021. According to one analyst, the rating for CRDF stock is "Strong Buy" and the 12-month stock price forecast is $12.0.

Is CRDF live data available?

CRDF Real-Time Quotes Live Data is currently not available 1D5D1M6MYTD1Y5YMAX Data is currently not available Last Five Real-Time Trades Data is currently not available View Latest Real Time Trades Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET).